CGH
NVO

Crossmark Global Holdings’s Novo Nordisk NVO Stock Holding History

Crossmark Global Holdings’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Sell
47,002
-6,740
-13% -$290K 0.03% 426
2026
Q1 		$1.98M Sell
53,742
-5,163
-9% -$245K 0.03% 434
2025
Q4 		$3M Buy
58,905
+1,540
+3% +$78.8K 0.04% 338
2025
Q3 		$3.18M Buy
57,365
+5,771
+11% +$338K 0.05% 332
2025
Q2 		$3.56M Sell
51,594
-343
-0.7% -$23.3K 0.06% 304
2025
Q1 		$3.61M Buy
51,937
+841
+2% +$69.5K 0.06% 291
2024
Q4 		$4.39M Sell
51,096
-1,500
-3% -$162K 0.08% 251
2024
Q3 		$6.26M Buy
52,596
+12,539
+31% +$1.67M 0.11% 216
2024
Q2 		$5.72M Buy
40,057
+1,455
+4% +$193K 0.11% 215
2024
Q1 		$4.96M Sell
38,602
-1,949
-5% -$232K 0.1% 234
2023
Q4 		$4.2M Buy
40,551
+487
+1% +$48.2K 0.09% 247
2023
Q3 		$3.73M Sell
40,064
-84
-0.2% -$7.4K 0.08% 253
2023
Q2 		$3.17M Buy
40,148
+892
+2% +$72.9K 0.07% 308
2023
Q1 		$3.12M Buy
39,256
+228
+0.6% +$16.2K 0.07% 297
2022
Q4 		$2.64M Sell
39,028
-354
-0.9% -$20.8K 0.07% 323
2022
Q3 		$1.96M Buy
39,382
+5,222
+15% +$280K 0.05% 364
2022
Q2 		$1.9M Sell
34,160
-1,520
-4% -$84.3K 0.05% 393
2022
Q1 		$1.98M Buy
35,680
+3,560
+11% +$183K 0.04% 421
2021
Q4 		$1.8M Buy
32,120
+510
+2% +$27.6K 0.04% 448
2021
Q3 		$1.52M Buy
31,610
+220
+0.7% +$10.6K 0.04% 478
2021
Q2 		$1.31M Sell
31,390
-3,700
-11% -$143K 0.03% 523
2021
Q1 		$1.18M Sell
35,090
-66,490
-65% -$2.37M 0.03% 541
2020
Q4 		$3.55M Sell
101,580
-7,806
-7% -$270K 0.09% 247
2020
Q3 		$3.8M Buy
109,386
+90
+0.1% +$3K 0.11% 207
2020
Q2 		$3.58M Buy
109,296
+57,090
+109% +$1.82M 0.1% 217
2020
Q1 		$1.57M Sell
52,206
-2,172
-4% -$64.7K 0.06% 338
2019
Q4 		$1.57M Sell
54,378
-68,272
-56% -$1.89M 0.04% 438
2019
Q3 		$3.17M Sell
122,650
-39,368
-24% -$995K 0.09% 245
2019
Q2 		$4.13M Buy
162,018
+3,018
+2% +$74.6K 0.12% 210
2019
Q1 		$4.16M Buy
159,000
+7,816
+5% +$192K 0.12% 209
2018
Q4 		$3.48M Sell
151,184
-1,000
-0.7% -$22.2K 0.11% 227
2018
Q3 		$3.59M Buy
152,184
+38,166
+33% +$931K 0.09% 262
2018
Q2 		$2.63M Sell
114,018
-79,174
-41% -$1.88M 0.07% 311
2018
Q1 		$4.76M Sell
193,192
-34,260
-15% -$899K 0.12% 204
2017
Q4 		$6.1M Buy
227,452
+53,922
+31% +$1.37M 0.15% 175
2017
Q3 		$4.18M Buy
+173,530
New +$3.92M 0.11% 229
2016
Q3 		$4.18M Buy
+173,530
New +$4.3M 0.11% 229

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Crossmark Global Holdings's NVO Position: Q2 2026 in Review

Crossmark Global Holdings reduced its Novo Nordisk (NVO) stake by 13% in Q2 2026, selling an estimated $290K and leaving 47,002 shares worth $2.25M. The position accounts for 0.03% of the portfolio, ranked #426.

Crossmark Global Holdings first reported a position in NVO in Q3 2016 and has held it in 37 quarters since. The position peaked at $6.26M in Q3 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Crossmark Global Holdings held 47,002 shares of Novo Nordisk worth $2.25M as of Q2 2026.
  • Crossmark Global Holdings sold 6,740 Novo Nordisk shares in Q2 2026, an estimated $290K.
  • Novo Nordisk made up 0.03% of Crossmark Global Holdings's portfolio in Q2 2026, its #426 holding.
  • Crossmark Global Holdings first reported a position in Novo Nordisk in Q3 2016 and has held it in 37 quarters since.
  • Crossmark Global Holdings's Novo Nordisk position peaked at $6.26M in Q3 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.